Europe GERD Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Channel, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Europe · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$1.53 BnPlaceholder estimate
Estimate 2025$1.58 Bn20.8% of the global market
Projected 2034$2.07 Bn 31.6%Adds $498.4 Mn over 9 forecast years
CAGR 2025–20343.1%Faster than 11% of 180 Pharmaceuticals markets here
Key players5
Europe is 20.82% of the global market.
Among regions, the largest is North America at $3.71 Bn.
35 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Europe GERD Treatment Market Analysis Executive Summary
GERD treatments relieve acid reflux and heartburn with acid-lowering medicines and procedures.
Key segments of the GERD Treatment market include treatment (Proton Pump Inhibitors, P-CABs and H2 Blockers) and channel (Prescription and Over-the-Counter).
Europe GERD Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Europe GERD Treatment Market Dynamics
Market Growth Drivers
Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the GERD Treatment market.
Opportunity
Microbiome-based treatments, earlier testing and digital gut-health programmes give the GERD Treatment market room to grow.
Market Restraints
Late diagnosis, stigma, limited specialist access and high prices of new medicines hold back the GERD Treatment market.
Competitive Landscape for GERD Treatment Market in Europe
The GERD Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for GERD Treatment Market in Europe
GERD Treatment in Europe: rules, payment and research
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).[1] In the countries we cover here, medicines are approved by ANSM (France)[2], BfArM (Germany)[3], AIFA (Italy)[4], Ministry of Health (Russia)[5], AEMPS (Spain)[6] and MHRA (UK)[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[8] ClinicalTrials.gov lists 35 studies on GERD Treatment that are recruiting, active or about to start in Europe.[9]
[9]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for GERD Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Treatment
4.2 By Channel
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Takeda
7.2 AstraZeneca
7.3 Phathom Pharmaceuticals
7.4 Haleon
7.5 Bayer AG
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The GERD Treatment market can be segmented based on various criteria, including treatment, channel and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in GERD Treatment right now, from free public sources.
Clinical trials
35 active trials in UK, Germany, France, Italy, Spain and Russia
Recruiting, about to start, or running now. Counted across the 6 countries we report on in Europe.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Placeholder estimate: about $1.58 Bn in 2025, rising to about $2.07 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the GERD Treatment market in Europe growing?
Placeholder estimate: about 3.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the GERD Treatment market report cover?
The report splits the market by treatment (Proton Pump Inhibitors, P-CABs, H2 Blockers, Antacids and more), channel (Prescription, Over-the-Counter) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the GERD Treatment market?
Key players include Takeda Pharmaceutical Company Ltd, AstraZeneca, Phathom Pharmaceuticals, Haleon PLC and Bayer AG.
What is driving the GERD Treatment market?
Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the GERD Treatment market.
Who regulates GERD Treatment in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on GERD Treatment are running in Europe?
35 studies are recruiting, active or about to start in Europe, counted across the 6 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on GERD Treatment?
PubMed lists 82 papers on GERD Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US
Canada
China
Japan
Germany
UK
Italy
France
Brazil
Spain
Ecuador
India
Saudi Arabia
Mexico
Australia
New Zealand
Russia
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Thailand
Singapore
Kenya
Aurobindo Pharma
Viatris
Dr Reddy’s Laboratories